CONDUIT PHARMACEUTICALS INC. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q4 2021 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Conduit Pharmaceuticals Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q4 2021 to Q2 2023.
  • Conduit Pharmaceuticals Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2023 was -$131K, a 49.1% decline year-over-year.
  • Conduit Pharmaceuticals Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending June 30, 2023 was $1.14M.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $1.14M -$131K -$43.1K -49.1% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $1.18M $157K +$410K Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $774K $751K +$756K Oct 1, 2022 Dec 31, 2022 10-K 2023-03-28
Q3 2022 $17.8K $364K Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-07
Q2 2022 -$87.8K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$254K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$4.38K Oct 19, 2021 Dec 31, 2021 10-K 2023-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.